ABVC BioPharma Seeks To Revolutionize Mental Health Treatment With A Safe Prozac Alternative, Boasting A MADRS Score Reduction Of -13.21 From Baseline Over 6 Weeks With A Placebo-subtracted Difference Of -4.1
ABVC BioPharma Seeks To Revolutionize Mental Health Treatment With A Safe Prozac Alternative, Boasting A MADRS Score Reduction Of -13.21 From Baseline Over 6 Weeks With A Placebo-subtracted Difference Of -4.1
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced in response to the discontinuation of Prozac[1] due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, "Radix Polygala", known as Polygala tenuifolia Willd or PDC-1421, can fill this void in the mental health market. With a robust formulation designed to reduce adverse effects, PDC-1421 promises to offer a safer and more effective solution for patients dealing with MDD and ADHD[2]. ABVC's ABV-1504 has completed Phase II clinical trials and is heading towards Phase III trials worldwide. ABVC holds patents for MDD and ADHD that have been approved in the USA and other countries and are valid until 2041.
ABVC BioPharma, Inc.（納斯達克：ABVC）是一家臨床階段的生物製藥公司，專注於眼科醫療、中樞神經系統（CNS）以及腫瘤/血液學的創新治療。今天，針對由於對副作用的擔憂不斷增加而停用Prozac[1]，ABVC表示其ABV-1504，活性藥物成分爲「Radix Polygala」，也稱爲Polygala tenuifolia Willd或PDC-1421，能夠填補心理健康市場的這一空缺。PDC-1421具有減少副作用的強效配方，承諾爲應對重度抑鬱症（MDD）和注意力缺陷多動障礙（ADHD）[2]的患者提供一個更安全、更有效的解決方案。ABVC的ABV-1504已經完成臨床二期試驗，並正在全球準備進入三期試驗。ABVC擁有MDD和ADHD的專利，這些專利已在美國和其他國家獲得批准，有效期至2041年。
The suspension of Prozac production highlights a rising demand for safer, all-natural alternatives to advanced mental health treatments, marking a pivotal moment for the pharmaceutical and mental health awareness industry. ABVC's ABV-1504 and 1505 have undergone rigorous clinical testing to ensure safety and efficacy, positioning them as real potential options for patients needing reliable, low-risk treatments.
Prozac生產的暫停突顯出對更安全、全自然替代先進心理健康治療的需求上升，這標誌着藥品和心理健康意識行業的一個關鍵時刻。ABVC的ABV-1504和1505經過嚴格的臨床測試，以確保安全性和有效性，使它們成爲需要可靠、低風險治療的患者真正的潛在選擇。
譯文內容由第三人軟體翻譯。
